Barely Significant
← all excerpts

Low-dose interleukin-2 in patients with mild to moderate Alzheimer's disease: a randomized clinical trial.

Alzheimers Res Ther · 2025 · PMC12231701 · PMID 40615880

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantp value < 0.001actually significant
No major changes in vital signs and weight were noted across the three arms throughout the 6-month treatment period. Secondary outcomes The increases in the percentage of CD4 + FoxP3 + CD25 high Treg from the baseline levels were highly significant ( p value < 0.001) across all the six timepoints (D8, D36, D64, D92, D120, D148) throughout the treatment phase in both the IL-2 q2wk and IL-2 q4wk arms, compared to the placebo arm.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.